Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Neuroimmunology

Treatment of anti-NMDA receptor encephalitis—time to be bold?

Nature Reviews Neurology volume 9, pages 187–189 (2013)Cite this article

Subjects

Treatment of anti-NMDA receptor encephalitis—a recently identified cause of autoimmune encephalitis—with aggressive immunosuppressive therapies has been a subject of debate. Now, a large observational cohort study suggests that most patients respond to immunotherapy, and that second-line therapies such as rituximab and cyclophosphamide may be beneficial.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dalmau, J. et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 7, 1091–1098 (2008).

    Article  CAS  Google Scholar 

  2. Titulaer, M. J. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 12, 157–165 (2013).

    Article  CAS  Google Scholar 

  3. Granerod, J. et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect. Dis. 10, 835–844 (2010).

    Article  Google Scholar 

  4. Gable, M. S., Sheriff, H., Dalmau, J., Tilley, D. H., & Glaser, C. A. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin. Infect. Dis. 54, 899–904 (2012).

    Article  CAS  Google Scholar 

  5. Lancaster, E. & Dalmau, J. Neuronal autoantigens—pathogenesis, associated disorders and antibody testing. Nat. Rev. Neurol. 8, 380–390 (2012).

    Article  CAS  Google Scholar 

  6. Gleichman, A. J., Spruce, L. A., Dalmau, J., Seeholzer, S. H. & Lynch, D. R. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J. Neurosci. 32, 11082–11094 (2012).

    Article  CAS  Google Scholar 

  7. Hughes, E. G. et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J. Neurosci. 30, 5866–5875 (2010).

    Article  CAS  Google Scholar 

  8. Zhang, Q. et al. Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. Neurobiol. Dis. 45, 610–615 (2012).

    Article  CAS  Google Scholar 

  9. Masdeu, J. C. et al. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. Am. J. Psychiatry 169, 1120–1121 (2012).

    Article  Google Scholar 

  10. van Baalen, A. et al. Febrile infection-related epilepsy syndrome without detectable autoantibodies and response to immunotherapy: a case series and discussion of epileptogenesis in FIRES. Neuropediatrics 43, 209–216 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pediatrics and Neurology, The Children's Hospital of Philadelphia, 502 Abramson Building, Philadelphia, 19104-4318, PA, USA

    Jessica A. Panzer & David R. Lynch

Authors
  1. Jessica A. Panzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David R. Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David R. Lynch.

Ethics declarations

Competing interests

D. R. Lynch receives royalties from Euroimmune for anti-NMDA receptor antibody testing. J. A. Panzer declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Panzer, J., Lynch, D. Treatment of anti-NMDA receptor encephalitis—time to be bold?. Nat Rev Neurol 9, 187–189 (2013). https://doi.org/10.1038/nrneurol.2013.31

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2013.31

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing